Precision will be attending the 2019 World Pharma Pricing & Market Access Congress on March 19th and 20th in Amsterdam!

In addition to visiting our sponsor booth, we encourage you to attend Precision thought leaders Basmah Khogeer and Nusayba Anjarwalla’s research presentation—full details follow:

Presentation:
Tumour-Agnostic Agents: Are They Fit for Reimbursement?
March 19, 2019
2:35pm
HTA Track

Summary:
In May 2017, the United States Food and Drug Administration (FDA) approved pembrolizumab, an anti-PD1 immunotherapy, for unresectable or metastatic solid tumours identified as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). This marked the first ever approval for a so-called tumour/site-agnostic indication for an oncology treatment. With several other oncology drugs in development for tumour/site-agnostic indications (e.g. larotrectinib and Debio 1347), the objective of this research was to explore the health technology assessment (HTA) challenges that may arise when assessing these drugs for reimbursement in Europe, should they obtain Marketing Authorization from the European Medicines Agency.

For more information on the Congress, please click here.